Lupin reports US approval for phytonadione prefilled syringe
The announcement concerns a 1 mg/0.5 mL single-dose product and an abbreviated new drug application.

Edivro Company News · Original attributed summary. Source announcement: 2026-10-08.
Lupin said the US Food and Drug Administration had approved its abbreviated new drug application for phytonadione injectable emulsion in a 1 mg/0.5 mL single-dose prefilled syringe. The company's announcement carries an October 8, 2026 dateline, although the webpage's publication metadata is dated October 9.
The company described the formulation as bioequivalent to the reference product from International Medication Systems. Its release identifies treatment and prevention of hypoprothrombinemia and vitamin K deficiency among the approved uses.
Is this a new molecule announcement?
The release concerns an abbreviated new drug application for a specified formulation. It is not an announcement of a newly discovered medicine or a comparison showing superior clinical outcomes.
What does the quoted market figure mean?
Lupin cited estimated US annual sales of US$52.3 million for phytonadione injectable emulsion, using IQVIA moving annual total data through August 2026. That estimate describes the cited product market, not Lupin's revenue or a sales forecast for its formulation.
The approval account here is attributed to Lupin's release. The article does not give dosing or treatment advice, and a product announcement should not replace the approved prescribing information or a clinician's assessment.
Questions about this story
These answers summarise the article and refer to its original reporting period.
Is this a new molecule announcement?
The release concerns an abbreviated new drug application for a specified formulation. It is not an announcement of a newly discovered medicine or a comparison showing superior clinical outcomes.
What does the quoted market figure mean?
Lupin cited estimated US annual sales of US$52.3 million for phytonadione injectable emulsion, using IQVIA moving annual total data through August 2026. That estimate describes the cited product market, not Lupin's revenue or a sales forecast for its formulation.
Publisher
Edivro Company News


